Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.

  • Read more about Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.

Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.

  • Read more about Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.

Loss of heterozygosity for chromosome 14q in neuroblastoma.

  • Read more about Loss of heterozygosity for chromosome 14q in neuroblastoma.

Comprehensive analysis of chromosome 1p deletions in neuroblastoma.

  • Read more about Comprehensive analysis of chromosome 1p deletions in neuroblastoma.

Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.

  • Read more about Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.

Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma.

  • Read more about Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma.

Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.

  • Read more about Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.

Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors.

  • Read more about Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors.

Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma.

  • Read more about Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma.

Lymphoblast morphology in predicting leukemic meningeal relapse with low chamber count and lymphoblasts.

  • Read more about Lymphoblast morphology in predicting leukemic meningeal relapse with low chamber count and lymphoblasts.

Pagination

  • Page 1
  • Next page ››
Subscribe to Medical and pediatric oncology

Pediatrics Home

MAKE A GIFT

© 2022 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                              Accessibility  Privacy Policy  Terms of Use  A-Z Website List